ACADIA to Host Conference Call and Webcast on Wednesday, November5, 2008, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Oct. 29, 2008—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the third quarterended September 30, 2008 on Wednesday, November 5, 2008, after theU.S. financial markets close. ACADIA's management will host aconference call and webcast on Wednesday, November 5, 2008, at 5:00p.m. Eastern Time to discuss ACADIA's financial results anddevelopment programs.
The conference call may be accessed by dialing 800-435-1261 forparticipants in the U.S. or Canada and 617-614-4076 for internationalcallers (reference passcode 29663518). A telephone replay of theconference call may be accessed through November 19, 2008 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 10534976). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until November 19, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA is focused ondeveloping a portfolio of its four most advanced product candidates,including pimavanserin in Phase III for Parkinson's disease psychosis,a compound in Phase II for chronic pain and a compound in Phase I forglaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA'spipeline emanate from discoveries made using its proprietary drugdiscovery platform and are directed at indications with large unmetmedical needs. ACADIA's corporate headquarters is located in SanDiego, California and it maintains research and development operationsin both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
(858) 558-2871
SOURCE: ACADIA Pharmaceuticals Inc.